Literature DB >> 18342708

Chemotherapeutic agents and the skin: An update.

Noushin Heidary1, Haley Naik, Susan Burgin.   

Abstract

UNLABELLED: Chemotherapeutic agents give rise to numerous well described adverse effects that may affect the skin, hair, mucous membranes, or nails. The mucocutaneous effects of longstanding agents have been extensively studied and reviewed. Over the last 2 decades, a number of new molecular entities for the treatment of cancer have been approved by the United States Food and Drug Administration (FDA). This article reviews the cutaneous toxicity patterns of these agents. It also reviews one drug that has not received FDA approval but is in use outside the United States and is important dermatologically. Particular emphasis is placed on the novel signal transduction inhibitors as well as on newer literature pertaining to previously described reactions. LEARNING
OBJECTIVES: At the completion of this learning activity, participants should able to list the newer chemotherapeutic agents that possess significant mucocutaneous side effects and describe the range of reactions that are seen with each drug. In addition, they should be able to formulate appropriate management strategies for these reactions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18342708     DOI: 10.1016/j.jaad.2008.01.001

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  39 in total

Review 1.  The cutaneous manifestations of haematological malignancy.

Authors:  Abigail Fogo; Anthony du Vivier
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

Review 2.  Cutaneous manifestations of cancer and chemotherapy.

Authors:  Emma Topham
Journal:  Clin Med (Lond)       Date:  2009-08       Impact factor: 2.659

Review 3.  Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review.

Authors:  Mario E Lacouture; David J Kopsky; Raphael Lilker; Fiona Damstra; Mecheline H M van der Linden; Azael Freites-Martinez; Mischa P M Nagel
Journal:  J Am Podiatr Med Assoc       Date:  2018-11

4.  Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.

Authors:  Masanori Ochi; Toshiro Kamoshida; Atsushi Ohkawara; Haruka Ohkawara; Nobushige Kakinoki; Shinji Hirai; Akinori Yanaka
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 5.  Dermatological adverse events with taxane chemotherapy.

Authors:  Vincent Sibaud; Nicole R Lebœuf; Henri Roche; Viswanath R Belum; Laurence Gladieff; Marion Deslandres; Marion Montastruc; Audrey Eche; Emmanuelle Vigarios; Florence Dalenc; Mario E Lacouture
Journal:  Eur J Dermatol       Date:  2016-10-01       Impact factor: 3.328

Review 6.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

7.  Vinblastine-induced Acral Hyperpigmentation.

Authors:  Annesha Chakraborti; Puneet Kaur Sahi
Journal:  Indian Pediatr       Date:  2020-06-15       Impact factor: 1.411

8.  Acneiform rash due to epidermal growth factor receptor inhibitors: high-level laser therapy as an innovative approach.

Authors:  M Gobbo; G Ottaviani; G Mustacchi; R Di Lenarda; M Biasotto
Journal:  Lasers Med Sci       Date:  2011-11-26       Impact factor: 3.161

Review 9.  Adverse reactions to targeted and non-targeted chemotherapeutic drugs with emphasis on hypersensitivity responses and the invasive metastatic switch.

Authors:  Brian A Baldo; Nghia H Pham
Journal:  Cancer Metastasis Rev       Date:  2013-12       Impact factor: 9.264

Review 10.  [Mucocutaneous infections in immunosuppression].

Authors:  P H Itin; M Battegay
Journal:  Internist (Berl)       Date:  2009-02       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.